Real-time enrollment status for this residual, progressive or recurrent grade ii or iii meningioma clinical trial
Current Status
Recruiting
Checked: August 30, 2026 at 5:28 AM UTC
| NCT Number | NCT05023018 |
| Recruiting Status | Recruiting |
| Condition | Residual, Progressive or Recurrent Grade II or III Meningioma |
| Phase | PHASE2 |
| Target Enrollment | 30 participants |
| Active Locations | 5 sites in the US |
| Sponsor | Neonc Technologies, Inc. |
| Last Updated on CT.gov | July 16, 2026 (Jul 16, 2026) |
As of August 30, 2026: Clinical trial NCT05023018 is currently recruiting participants. This phase2 study for residual, progressive or recurrent grade ii or iii meningioma is actively seeking new participants at 5 locations across the United States. The study is sponsored by Neonc Technologies, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05023018 is actively recruiting participants as of August 30, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 5 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05023018 was last updated Jul 16, 2026 (July 16, 2026). HelloStudys verifies this status automatically.